Rituxem 100mg/10ml Injection

• Rheumatoid arthritis
• Blood cancer (Chronic lymphocytic leukemia)
• Non-Hodgkin lymphoma (NHL)
• Granulomatosis with polyangiitis
• Microscopic polyangiitis

Every medication has several side effects, Rituxem 100mg Injection also causes various symptoms. Some of them are resolve on their own and some need proper medical attention to treat the symptoms:

• Anemia
• Muscle spasm
• Headache
• Urinary tract infection
• Fever, chills, and shivering
• Inflammation of nasal cavities
• Cough, sore throat
• Loss of hair
• Increased or decreased blood pressure
• Chest pain
• Hypersensitivity reactions
• Hepatitis B viral infection
• Memory loss, trouble thinking, difficulty in walking​

Rituxem 10ml Injection should be correctly administered by a healthcare. Do not self-administer as doctor will guide you better about the dosage and duration. It is given through intravenous infusion only by a nurse in hospital as it requires careful monitoring.

​

Rituxem 100mg Injection is a monoclonal antibody that attaches to CD20 proteins on B cells and help the immune system to destroy these cells. This is helpful when B cells are causing disease (cancer and autoimmunity), thereby reducing abnormal or overall B cells activity in conditions such as certain cancers and autoimmune disease.​

• Onrust, S. V., Lamb, H. M., & Barman Balfour, J. A. (1999). Rituximab. Drugs, 58(1), 79-88. https://pubmed.ncbi.nlm.nih.gov/10439931/
  
• Weiner, G. J. (2010, April). Rituximab: mechanism of action. In Seminars in hematology (Vol. 47, No. 2, pp. 115-123). WB Saunders. https://pubmed.ncbi.nlm.nih.gov/20350658/
  
• Cerny, T., Borisch, B., Introna, M., Johnson, P., & Rose, A. L. (2002). Mechanism of action of rituximab. Anti-cancer drugs, 13, S3-S10. https://pubmed.ncbi.nlm.nih.gov/12710585/
  
• Johnson, P. W. M., & Glennie, M. J. (2001). Rituximab: mechanisms and applications. British journal of cancer, 85(11), 1619-1623. https://pubmed.ncbi.nlm.nih.gov/11742477/
  
• Rezvani, A. R., & Maloney, D. G. (2011). Rituximab resistance. Best practice & research Clinical haematology, 24(2), 203-216. https://pubmed.ncbi.nlm.nih.gov/21658619/​